Level C· Early human research exploring benefitsRetrospective StudyPubMed

Patient Age Is Not a Determinant of 12-Month Pain Response After Autologous Adipose-Derived Stromal Vascular Fraction Injection for Knee Osteoarthritis.

Kim YS., Koh YG.

Retrospective Study with a reported sample of 357 on Knee Osteoarthritis, Osteoarthritis, published in Medicina (Kaunas) (2026) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
Medicina (Kaunas) (2026)
Country
Switzerland
Reported sample size
357
Source database
PubMed
PMID
42356058
DOI
10.3390/medicina62061044

Abstract (original English)

Background: Autologous adipose-derived stromal vascular fraction (SVF) is increasingly used for symptomatic knee osteoarthritis (OA), but it remains uncertain whether patient age should influence candidacy. We examined whether age was related to 12-month pain response after intra-articular SVF administration. Methods: This retrospective knee-level analysis included 357 knees from 266 patients with Kellgren-Lawrence grade II-IV OA treated with adipose-derived SVF and followed for at least 12 months. Pain was assessed with the visual analog scale (VAS). Group comparisons and Spearman correlation analyses were used to explore relationships between age, baseline variables, injected cell number, and pain outcomes. Results: VAS scores improved from 6.5 ± 1.2 before treatment to 3.1 ± 1.6 at final assessment ( p < 0.01). Age did not show a significant association with baseline pain ( p = 0.128), final pain ( p = 0.088), or measured baseline factors. Higher body mass index, more severe radiographic OA, and lower SVF cell number were associated with less favorable final pain scores. No serious treatment-related adverse event was identified. Conclusions: SVF injection was followed by significant pain reduction at 12 months. In this cohort, chronological age was not a meaningful determinant of response, whereas metabolic burden, structural OA severity, and delivered cell dose were more re

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansOsteoarthritis, KneeMaleFemaleRetrospective StudiesAge FactorsMiddle AgedAgedInjections, Intra-ArticularPain Measurement

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research